Training activity information
Details
Analyse, interpret and draft a clinical report for risk stratification and treatment for CLL, to include:
- IGH somatic hypermutation
- TP53/17p
Type
Entrustable training activity (ETA)
Evidence requirements
Evidence the activity has been undertaken by the trainee repeatedly, consistently, and effectively over time, in a range of situations. This may include occasions where the trainee has not successfully achieved the outcome of the activity themselves. For example, because it was not appropriate to undertake the task in the circumstances or the trainees recognised their own limitations and sought help or advice to ensure the activity reached an appropriate conclusion.
Reflection at multiple timepoints on the trainee learning journey for this activity.
Considerations
Considerations are suggestions about what may be useful for the trainee to think about while undertaking a training activity. They should not be considered as a mandatory checklist. Trainees should not be expected to demonstrate or provide evidence for each of the considerations listed.
- Principles of the molecular testing strategy
- IQC and EQA
- Best practice guidelines for reporting, including recommendations for patient treatment and management, follow up, further testing or clinical trials if relevant
- Correct scientific and clinical terminology, including HGVS nomenclature
- Communication of complex scientific information to the multidisciplinary team
Relevant learning outcomes
| # | Outcome |
|---|---|
| # 4 |
Outcome
Analyse, interpret and prepare interpretive reports for common haematological malignancies, including results for somatic variants, clonality, and somatic hypermutation. |
| # 5 |
Outcome
Interpret the associated IQC and EQA of the laboratory tests for investigation of haematological malignancies. |
| # 6 |
Outcome
Practice with the relevant specialties for the diagnosis, monitoring and management of haematological malignancies. |